Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
TheFly reported on April 9 that Northland initiated coverage of SPRY with an Outperform rating and a $25 price target. The firm highlighted Neffy, a needle-free intranasal epinephrine therapy, as a key innovation addressing long-standing challenges associated with injectable epinephrine use. It expects adoption to be supported by both new patient prescriptions and switching from existing injectable treatments, driven by improved ease of use and accessibility. Linked to that, on March 27, the U.S. FDA approved an update to the prescribing information for neffy 1 mg (epinephrine nasal spray), removing prior age restrictions and allowing use in all patients weighing at least 33 lbs for emergency treatment of type 1 allergic reactions, including anaphylaxis. Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver The previous requirement limiting use to children aged four and older was eliminated. The revised labeling also provides updat
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]Yahoo! Finance
- neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)GlobeNewswire
- ARS Pharmaceuticals (SPRY) is now covered by Northland Securities. They set an "outperform" rating and a $25.00 price target on the stock.MarketBeat
- ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) LabelGlobeNewswire
SPRY
Earnings
- 3/9/26 - In-Line
SPRY
Sec Filings
- 4/29/26 - Form ARS
- 4/29/26 - Form DEFA14A
- 4/29/26 - Form DEF
- SPRY's page on the SEC website